Quantify any protein, in any sample, with any modification, without antibodies
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
November 17-20, 2024 Austin, TX Booth #302 ACT is a global community of professional scientists representing the pharmaceutical and biotech industries...
November 14, 2024 Inotiv is incredibly pleased to announce that we’ve received a $1.8 million dollar grant to develop a novel chronic kidney disease (CKD) in vivo model that can bridge the...
November 07, 2024 WEST LAFAYETTE, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization spec...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
General Toxicology
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
